Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria
Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of , predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide. The primary objective was to evaluate the comparative effectiveness of pan-genotypic therapies for the treatmen...
Gespeichert in:
| Veröffentlicht in: | Journal of comparative effectiveness research 2019-05, Vol.8 (7), p.455-459 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 7 |
| container_start_page | 455 |
| container_title | Journal of comparative effectiveness research |
| container_volume | 8 |
| creator | Djambazov, Slaveyko Slavchev, Georgi Encheva, Marta Mitova, Radoslava Vekov, Toni |
| description | Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of
, predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide.
The primary objective was to evaluate the comparative effectiveness of pan-genotypic therapies for the treatment of patients with HCV infection in Bulgaria.
The databases MEDLINE, EMBASE, Cochrane Library, PubMed and
were searched to identify studies evaluating the therapeutic efficacy of sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of HCV patients.
The range of sustained virologic response rates among all genotypes achieved after therapy with sofosbuvir/velpatasvir/voxilaprevir was 92-100% (8-week therapy) in treatment-naive patients and 99-100% (12-week therapy) in experienced patients. The range of sustained virologic response rates with glecaprevir/pibrentasvir was 91-100% (12-week therapy) and 97-100% (12-week therapy) with sofosbuvir/velpatasvir.
Sofosbuvir/velpatasvir/voxilaprevir is a noninferior therapy offering a simple and short-term treatment regimen with high efficacy, favorable safety profile and good tolerability. |
| doi_str_mv | 10.2217/cer-2018-0143 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2199185525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275089884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-15c1f2be39e846754c7a46cef62e487ddf096267d582abe9b936c8f7a1400afa3</originalsourceid><addsrcrecordid>eNp1kc1rFTEUxYNUbKldupWAm25G8zmTLOujVaHgRtchL--mL-VNMiaZlq7815tx2i4K3k3Ogd89XHIQ-kDJZ8bo8MVB7hihqiNU8DfohBHBup5TfvSiiTxGZ6Xckja9Elqyd-iYE80Ip_QE_d2kcbLZ1nAHGLwHt6gIpeDk8WRjdwMx1YcpOFz3kO0UoGCf8uJwzWDrCLGucA1NFnwf6h7vYfE1FLzBdyHPBYf4Lz3FpvDX-XBjc7Dv0VtvDwXOnt5T9Pvq8tfme3f989uPzcV15_hAa0elo55tgWtQoh-kcIMVvQPfMxBq2O080T3rh51UzG5BbzXvnfKDpYIQ6y0_Redr7pTTnxlKNWMoDg4HGyHNxTCqNVVSMtnQT6_Q2zTn2K4zjA2SKK2UaFS3Ui6nUjJ4M-Uw2vxgKDFLOaaVY5ZyzFJO4z8-pc7bEXYv9HMVDdAr4Oc6ZyiufaYDs7q2EVyI8J_wR1KNn3E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275089884</pqid></control><display><type>article</type><title>Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Djambazov, Slaveyko ; Slavchev, Georgi ; Encheva, Marta ; Mitova, Radoslava ; Vekov, Toni</creator><creatorcontrib>Djambazov, Slaveyko ; Slavchev, Georgi ; Encheva, Marta ; Mitova, Radoslava ; Vekov, Toni</creatorcontrib><description>Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of
, predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide.
The primary objective was to evaluate the comparative effectiveness of pan-genotypic therapies for the treatment of patients with HCV infection in Bulgaria.
The databases MEDLINE, EMBASE, Cochrane Library, PubMed and
were searched to identify studies evaluating the therapeutic efficacy of sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of HCV patients.
The range of sustained virologic response rates among all genotypes achieved after therapy with sofosbuvir/velpatasvir/voxilaprevir was 92-100% (8-week therapy) in treatment-naive patients and 99-100% (12-week therapy) in experienced patients. The range of sustained virologic response rates with glecaprevir/pibrentasvir was 91-100% (12-week therapy) and 97-100% (12-week therapy) with sofosbuvir/velpatasvir.
Sofosbuvir/velpatasvir/voxilaprevir is a noninferior therapy offering a simple and short-term treatment regimen with high efficacy, favorable safety profile and good tolerability.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer-2018-0143</identifier><identifier>PMID: 30920311</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Bulgaria ; Carbamates - therapeutic use ; Clinical trials ; comparative effectiveness ; Drug Therapy, Combination ; Genotype ; Genotype & phenotype ; HCV ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatology ; Heterocyclic Compounds, 4 or More Rings - administration & dosage ; Heterocyclic Compounds, 4 or More Rings - therapeutic use ; Humans ; Infections ; Liver diseases ; Macrocyclic Compounds - therapeutic use ; Mortality ; Patients ; Sofosbuvir - therapeutic use ; Studies ; Sulfonamides - therapeutic use ; Sustained Virologic Response ; treatment</subject><ispartof>Journal of comparative effectiveness research, 2019-05, Vol.8 (7), p.455-459</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd May 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-15c1f2be39e846754c7a46cef62e487ddf096267d582abe9b936c8f7a1400afa3</citedby><cites>FETCH-LOGICAL-c371t-15c1f2be39e846754c7a46cef62e487ddf096267d582abe9b936c8f7a1400afa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30920311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Djambazov, Slaveyko</creatorcontrib><creatorcontrib>Slavchev, Georgi</creatorcontrib><creatorcontrib>Encheva, Marta</creatorcontrib><creatorcontrib>Mitova, Radoslava</creatorcontrib><creatorcontrib>Vekov, Toni</creatorcontrib><title>Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of
, predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide.
The primary objective was to evaluate the comparative effectiveness of pan-genotypic therapies for the treatment of patients with HCV infection in Bulgaria.
The databases MEDLINE, EMBASE, Cochrane Library, PubMed and
were searched to identify studies evaluating the therapeutic efficacy of sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of HCV patients.
The range of sustained virologic response rates among all genotypes achieved after therapy with sofosbuvir/velpatasvir/voxilaprevir was 92-100% (8-week therapy) in treatment-naive patients and 99-100% (12-week therapy) in experienced patients. The range of sustained virologic response rates with glecaprevir/pibrentasvir was 91-100% (12-week therapy) and 97-100% (12-week therapy) with sofosbuvir/velpatasvir.
Sofosbuvir/velpatasvir/voxilaprevir is a noninferior therapy offering a simple and short-term treatment regimen with high efficacy, favorable safety profile and good tolerability.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Bulgaria</subject><subject>Carbamates - therapeutic use</subject><subject>Clinical trials</subject><subject>comparative effectiveness</subject><subject>Drug Therapy, Combination</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>HCV</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatology</subject><subject>Heterocyclic Compounds, 4 or More Rings - administration & dosage</subject><subject>Heterocyclic Compounds, 4 or More Rings - therapeutic use</subject><subject>Humans</subject><subject>Infections</subject><subject>Liver diseases</subject><subject>Macrocyclic Compounds - therapeutic use</subject><subject>Mortality</subject><subject>Patients</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Studies</subject><subject>Sulfonamides - therapeutic use</subject><subject>Sustained Virologic Response</subject><subject>treatment</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1rFTEUxYNUbKldupWAm25G8zmTLOujVaHgRtchL--mL-VNMiaZlq7815tx2i4K3k3Ogd89XHIQ-kDJZ8bo8MVB7hihqiNU8DfohBHBup5TfvSiiTxGZ6Xckja9Elqyd-iYE80Ip_QE_d2kcbLZ1nAHGLwHt6gIpeDk8WRjdwMx1YcpOFz3kO0UoGCf8uJwzWDrCLGucA1NFnwf6h7vYfE1FLzBdyHPBYf4Lz3FpvDX-XBjc7Dv0VtvDwXOnt5T9Pvq8tfme3f989uPzcV15_hAa0elo55tgWtQoh-kcIMVvQPfMxBq2O080T3rh51UzG5BbzXvnfKDpYIQ6y0_Redr7pTTnxlKNWMoDg4HGyHNxTCqNVVSMtnQT6_Q2zTn2K4zjA2SKK2UaFS3Ui6nUjJ4M-Uw2vxgKDFLOaaVY5ZyzFJO4z8-pc7bEXYv9HMVDdAr4Oc6ZyiufaYDs7q2EVyI8J_wR1KNn3E</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Djambazov, Slaveyko</creator><creator>Slavchev, Georgi</creator><creator>Encheva, Marta</creator><creator>Mitova, Radoslava</creator><creator>Vekov, Toni</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190501</creationdate><title>Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria</title><author>Djambazov, Slaveyko ; Slavchev, Georgi ; Encheva, Marta ; Mitova, Radoslava ; Vekov, Toni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-15c1f2be39e846754c7a46cef62e487ddf096267d582abe9b936c8f7a1400afa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Bulgaria</topic><topic>Carbamates - therapeutic use</topic><topic>Clinical trials</topic><topic>comparative effectiveness</topic><topic>Drug Therapy, Combination</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>HCV</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatology</topic><topic>Heterocyclic Compounds, 4 or More Rings - administration & dosage</topic><topic>Heterocyclic Compounds, 4 or More Rings - therapeutic use</topic><topic>Humans</topic><topic>Infections</topic><topic>Liver diseases</topic><topic>Macrocyclic Compounds - therapeutic use</topic><topic>Mortality</topic><topic>Patients</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Studies</topic><topic>Sulfonamides - therapeutic use</topic><topic>Sustained Virologic Response</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Djambazov, Slaveyko</creatorcontrib><creatorcontrib>Slavchev, Georgi</creatorcontrib><creatorcontrib>Encheva, Marta</creatorcontrib><creatorcontrib>Mitova, Radoslava</creatorcontrib><creatorcontrib>Vekov, Toni</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Djambazov, Slaveyko</au><au>Slavchev, Georgi</au><au>Encheva, Marta</au><au>Mitova, Radoslava</au><au>Vekov, Toni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>8</volume><issue>7</issue><spage>455</spage><epage>459</epage><pages>455-459</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>Hepatitis C virus (HCV) is a positive-stranded RNA virus which belongs to the family of
, predominantly infecting liver hepatocytes. HCV infection is a major cause for morbidity worldwide.
The primary objective was to evaluate the comparative effectiveness of pan-genotypic therapies for the treatment of patients with HCV infection in Bulgaria.
The databases MEDLINE, EMBASE, Cochrane Library, PubMed and
were searched to identify studies evaluating the therapeutic efficacy of sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of HCV patients.
The range of sustained virologic response rates among all genotypes achieved after therapy with sofosbuvir/velpatasvir/voxilaprevir was 92-100% (8-week therapy) in treatment-naive patients and 99-100% (12-week therapy) in experienced patients. The range of sustained virologic response rates with glecaprevir/pibrentasvir was 91-100% (12-week therapy) and 97-100% (12-week therapy) with sofosbuvir/velpatasvir.
Sofosbuvir/velpatasvir/voxilaprevir is a noninferior therapy offering a simple and short-term treatment regimen with high efficacy, favorable safety profile and good tolerability.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30920311</pmid><doi>10.2217/cer-2018-0143</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6305 |
| ispartof | Journal of comparative effectiveness research, 2019-05, Vol.8 (7), p.455-459 |
| issn | 2042-6305 2042-6313 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2199185525 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Antiviral Agents - therapeutic use Bulgaria Carbamates - therapeutic use Clinical trials comparative effectiveness Drug Therapy, Combination Genotype Genotype & phenotype HCV Hepacivirus - genetics Hepatitis Hepatitis C hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatology Heterocyclic Compounds, 4 or More Rings - administration & dosage Heterocyclic Compounds, 4 or More Rings - therapeutic use Humans Infections Liver diseases Macrocyclic Compounds - therapeutic use Mortality Patients Sofosbuvir - therapeutic use Studies Sulfonamides - therapeutic use Sustained Virologic Response treatment |
| title | Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T07%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20effectiveness%20of%20pan-genotypic%20therapies%20for%20the%20treatment%20of%20patients%20with%20hepatitis%20C%20virus%20infection%20in%20Bulgaria&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Djambazov,%20Slaveyko&rft.date=2019-05-01&rft.volume=8&rft.issue=7&rft.spage=455&rft.epage=459&rft.pages=455-459&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer-2018-0143&rft_dat=%3Cproquest_cross%3E2275089884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275089884&rft_id=info:pmid/30920311&rfr_iscdi=true |